CN114933562A - 基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法 - Google Patents
基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法 Download PDFInfo
- Publication number
- CN114933562A CN114933562A CN202210769396.0A CN202210769396A CN114933562A CN 114933562 A CN114933562 A CN 114933562A CN 202210769396 A CN202210769396 A CN 202210769396A CN 114933562 A CN114933562 A CN 114933562A
- Authority
- CN
- China
- Prior art keywords
- chloroquine
- synthesizing
- reaction
- hydroxybenzyl
- chloroquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960003677 chloroquine Drugs 0.000 title claims abstract description 53
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 title claims abstract description 51
- -1 (2-hydroxybenzyl) disubstituted phosphine oxide Chemical class 0.000 title claims abstract description 36
- 238000006555 catalytic reaction Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 238000005859 coupling reaction Methods 0.000 claims abstract description 16
- NDRZSRWMMUGOBP-UHFFFAOYSA-N 4-Amino-7-chloroquinoline Chemical compound ClC1=CC=C2C(N)=CC=NC2=C1 NDRZSRWMMUGOBP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims abstract description 8
- 238000006722 reduction reaction Methods 0.000 claims abstract description 8
- OAQYRNDEOJQVBN-UHFFFAOYSA-N 5-(diethylamino)pentan-2-ol Chemical compound CCN(CC)CCCC(C)O OAQYRNDEOJQVBN-UHFFFAOYSA-N 0.000 claims abstract description 7
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 238000005694 sulfonylation reaction Methods 0.000 claims abstract description 4
- 238000005576 amination reaction Methods 0.000 claims abstract description 3
- 238000007670 refining Methods 0.000 claims abstract description 3
- 230000006103 sulfonylation Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 230000035484 reaction time Effects 0.000 claims description 10
- 239000007858 starting material Substances 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 239000011591 potassium Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 claims description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 3
- 229940011051 isopropyl acetate Drugs 0.000 claims description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000010189 synthetic method Methods 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- NQWHOPCJTGVYOX-UHFFFAOYSA-N 2-(diphenylphosphorylmethyl)phenol Chemical compound OC1=CC=CC=C1CP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 NQWHOPCJTGVYOX-UHFFFAOYSA-N 0.000 claims description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- OZDCZHDOIBUGAJ-UHFFFAOYSA-N 4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C=C1 OZDCZHDOIBUGAJ-UHFFFAOYSA-N 0.000 claims description 2
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 15
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 3
- 238000005580 one pot reaction Methods 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract 1
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000012535 impurity Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CAPCBAYULRXQAN-UHFFFAOYSA-N 1-n,1-n-diethylpentane-1,4-diamine Chemical compound CCN(CC)CCCC(C)N CAPCBAYULRXQAN-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005265 energy consumption Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- XMFXTXKSWIDMER-UHFFFAOYSA-N 7-chloro-1h-quinolin-4-one Chemical compound ClC1=CC=C2C(O)=CC=NC2=C1 XMFXTXKSWIDMER-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000102136 Pectiantia ovalis Species 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000006204 deethylation Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0255—Phosphorus containing compounds
- B01J31/0267—Phosphines or phosphonium compounds, i.e. phosphorus bonded to at least one carbon atom, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, the other atoms bonded to phosphorus being either carbon or hydrogen
- B01J31/0268—Phosphonium compounds, i.e. phosphine with an additional hydrogen or carbon atom bonded to phosphorous so as to result in a formal positive charge on phosphorous
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
- B01J2231/4277—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues
- B01J2231/4283—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues using N nucleophiles, e.g. Buchwald-Hartwig amination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及一种氯喹的高效制备方法,所述的合成方法包括步骤:以4‑氨基‑7‑氯喹啉为起始原料,先与取代磺酰氯进行磺酰胺化反应制得4‑取代磺酰胺基‑7‑氯喹啉,然后在(2‑羟基苄基)二取代氧化膦催化下,与5‑二乙胺基‑2‑戊醇进行C‑N偶联反应,然后在有机溶剂中碱解、还原、回收(2‑羟基苄基)二取代氧化膦、萃取、浓缩、精制得到氯喹。采用本发明提供的合成方法,实现了一锅四步高效制备氯喹,大大降低了生产周期,提高了生产效率,降低了生产成本。
Description
技术领域
本发明涉及药物化学领域,特别涉及用于治疗疟疾、系统性红斑狼疮、类风湿性关节炎、阿米巴肝炎等疾病的氯喹的制备,具体涉及一种基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法。
背景技术
氯喹(Chloroquine,CQ,1),化学名称:N4-(7-氯-4-喹啉基)-N1,N1-二乙基-1,4-戊二胺,CAS号:54-05-7,化学结构如下:
氯喹于1934年被安德萨格和他的同事在拜耳实验室被发现,并将其命名为“Resochin”,于1947年被引入临床实践,用于预防治疗疟疾(间日疟原虫、卵形疟原虫和疟疾),非常高效且对人类的耐受性良好。此外,氯喹还用于治疗类风湿性关节炎、红斑狼疮和阿米巴肝炎。另外,氯喹还能抑制新冠病毒和免疫调节活性,可以协同增强其在体内的抗病毒效果,因此,2020年公布的《新型冠状病毒肺炎诊疗指南(试行第六版)》将磷酸氯喹作为新冠病毒的推荐用药,并指出应严格观察其使用的不良反应。
现有氯喹生产方法的反应过程如下:向事先预热为熔融状态的4,7-二氯喹啉(2)中加入热熔的苯酚,加热至115-120℃,搅拌反应1h。然后缓慢滴加2-氨基-5-二乙胺基戊烷(3),升温至137-139℃进行C-N偶联反应,反应12小时后反应结束,待反应液冷却80℃,加入液碱至pH=14,搅拌均匀,然后在60-70℃用氯仿萃取游离的氯喹,提取3-4次后合并有机层,水洗至中性,蒸干溶剂得氯喹粗品,用乙醚重结晶得到氯喹产品。具体路线如下:
该方法主要存在以下不足:i)反应用苯酚做溶剂,苯酚具有剧毒且有腐蚀性,对人员和环境伤害极大,并在后处理过程中转变成苯酚钠水溶液形成有害的含酚废水,增加了三废处理的难度;ii)C-N偶联反应,温度高,时间长,能耗大,而高温下长时间搅拌导致杂质的含量与数量的增加,特别是产生很难去除的脱乙基杂质;iii)萃取溶剂氯仿为一类溶剂,致癌,对环境不友好;iv)重结晶溶剂乙醚易燃易爆,安全隐患大。
专利CN 111662229 A公开一种氯喹的制备工艺:以4,7-二氯喹啉(2)与2-氨基-5-二乙胺基戊烷(3)为原料,升温至135-140℃,在无溶剂情况下进行C-N偶联反应24h。反应结束后,待反应液降温至100℃,向反应液中加入6%的氢氧化钠水溶液至pH=11-12,充分搅拌后加入二氯甲烷,分层。有机层用纯化水洗涤,干燥,抽滤旋干。加入异丙醚重结晶,抽滤,烘干,制得氯喹,总收率79.9%。具体路线如下:
该方法主要存在以下不足:i)C-N偶联反应温度高达135-140℃,反应时间长达24h,能耗高;ii)易生成杂质影响反应收率且后处理除杂困难,影响产品纯度;iii)我们在实验中发现,由于4,7-二氯喹啉在高温下升华严重而损失较大,导致收率达不到专利报道的水准。
专利CN112830894A公开一种氯喹的制备工艺:向反应瓶中加入原料4,7-二氯喹啉(2)、 2-氨基-5-二乙胺基戊烷(3),抗氧化剂亚硫酸钠,缚酸剂N,N-二异丙基乙基胺,溶剂异丙醇。升温将异丙醇蒸出至反应液内温达到133℃,在133-138℃下,进行C-N偶联反应12h。反应结束后,向反应液中加入氢氧化钠水溶液至pH=11,在90-95℃下,保温搅拌0.5h。待反应液降温至70℃,加入醋酸异丙酯,分液,弃水相,有机相水洗至中性后适量浓缩后重结晶,得到氯喹纯品,收率为:80.1%。具体路线如下:
该方法主要存在以下不足:i)C-N偶联反应温度高、反应时间长,能耗高;ii)易生成杂质影响反应收率且后处理除杂困难,影响产品纯度;iii)N,N-二异丙基乙基胺于133-138℃长时间的情况下,反应系统颜色呈现深黑色,导致产品色泽很难达标;iv)我们在实验中发现,由于原料4,7-二氯喹啉在高温下仍有部分升华而部分损失,导致收率达不到专利报道的水准。
Liang,Wanyi等人(Org.Lett.2020,22(21):8291-8295)介绍了一种氯喹的制备方法:向反应瓶中加入7-氯-4-羟基喹啉(14)、2-氨基-5-二乙胺基戊烷(3)、Pd/C、HCO2NH4、K2S2O5水溶液,在氮气保护下120℃进行C-N偶联反应16h。冷却至室温后,通过真空除去溶剂,浓缩反应混合物,残余物经过柱层析,用石油醚洗脱:乙酸乙酯,得到氯喹(1)收率为56%。具体路线如下:
该方法主要存在以下不足:i)C-N偶联反应温度高、反应时间长,能耗高;ii)产生了大量的难分离的脱氯杂质(12),导致产品质量差,收率较低(仅56%);iii)使用的过渡金属催化剂Pd的价格昂贵,增加了原料成本;iv)最终产物需要柱层析获得,该方法不适用于工业化大生产。
上述各个路线都存在C-N偶联反应温度高、时间长、试剂毒性大、污染环境、杂质多,产品质量差等不足,需要对该制备氯喹的C-N偶联工艺进行绿色改进。
发明内容
为了克服现有技术中的不足,本发明提供一种收率可以有所提高、反应条件温和可控、反应比较完全,杂质很少的基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法。
本发明的该氯喹的合成方法,所述的合成方法包括步骤:
(1)4-氨基-7-氯喹啉与取代磺酰氯进行磺酰胺化反应制得4-取代磺酰胺基-7-氯喹啉;
(2)在(2-羟基苄基)二取代氧化膦催化下,4-取代磺酰胺基-7-氯喹啉与5-二乙胺基-2- 戊醇进行C-N偶联反应;
(3)然后在有机溶剂中经碱解反应、还原反应、回收(2-羟基苄基)二取代氧化膦、萃取、浓缩、精制得到氯喹。
较佳地,所述的步骤(1)中所述的取代磺酰氯为对硝基苯磺酰氯、对三氟甲基苯磺酰氯、甲烷磺酰氯或三氟甲基磺酰氯,优选为三氟甲基磺酰氯。
较佳地,所述的步骤(2)中所述的为(2-羟基苄基)二取代氧化膦为(2-羟基苄基)二苯基氧化膦、(2-羟基-5-叔丁基苄基)二苯基氧化膦或(2-羟基苄基)二环己基氧化膦,优选(2-羟基 -5-叔丁基苄基)二苯基氧化膦。
较佳地,所述的步骤(3)中有机溶剂为四氢呋喃、甲基四氢呋喃、甲醇或乙醇等1-6个碳原子的有机醇、二氧六环、乙二醇或丙二醇的单一溶剂或混合溶剂,优选乙醇。
较佳地,所述的步骤(3)中用于碱解反应的碱为1-6个碳原子的有机醇钠、1-6个碳原子的有机醇钾、1-6个碳原子的有机醇锂、氢氧化钠、氢氧化钾、氢氧化锂、氢化钠、氨基钠、三乙胺、二异丙基乙基胺或DBU中的单一试剂或混合试剂,优选乙醇钠。
较佳地,所述的步骤(3)中用于还原反应的还原剂为硼氢化钾、硼氢化钠或氰基硼氢化钠中的单一试剂或混合试剂,优选硼氢化钾。
较佳地,所述的步骤(1)中磺酰胺化反应时间为2~10h,优选4~6h;反应温度为-10~ 110℃,优选20~25℃。
较佳地,所述的步骤(2)中C-N偶联反应时间为8~30h,优选15~20h;反应温度为60~150℃,优选100~110℃。
较佳地,所述的步骤(3)中碱解反应时间为4~12h,优选6~8h;反应温度为-10~110℃,优选20~25℃。
较佳地,所述的步骤(3)中还原反应时间为0.5~10h,优选1~2h;反应温度为-10~ 110℃,优选20~25℃。
较佳地,所述的步骤(1)中4-氨基-7-氯喹啉与取代磺酰氯的摩尔比为1:0.9~1:2.0,优选1:1.1~1:1.2。
较佳地,所述的步骤(2)中的5-二乙胺基-2-戊醇与起始原料4-氨基-7-氯喹啉的摩尔比为0.9:1~2.0:1,优选1.2:1。
较佳地,所述的步骤(2)中的(2-羟基苄基)二取代氧化膦与起始原料4-氨基-7-氯喹啉的摩尔比为0.01:1~0.2:1,优选0.05:1~0.1:1。
较佳地,碱解反应中的碱与起始原料4-氨基-7-氯喹啉的摩尔比为0.9:1~2.0:1,优选1.2:1。
较佳地,还原反应中的还原剂与起始原料4-氨基-7-氯喹啉的摩尔比为0.3:1~1.0:1,优选0.35:1~0.4:1。
较佳地,重结晶溶剂为乙酸乙酯、乙酸异丙酯、乙酸甲酯、乙酸丁酯、丙酮、甲基异丁基酮、甲基叔丁基醚、异丙醇或甲苯的单一溶剂或混合溶剂,优选乙酸乙酯。
本发明的提供的氯喹的合成方法的优点如下:
1)实现了一锅四步高效制备氯喹,大大降低了生产周期,提高了生产效率,降低了生产成本;
2)以价格相对便宜50%的侧链5-二乙胺基-2-戊醇,在(2-羟基苄基)二取代氧化膦的催化下,通过羟基活化途径,实现在比较温和的条件下完成了C-N偶联反应,降低了成本;
3)利用简单的酸碱处理法高收率(94.3%)的回收(2-羟基苄基)二取代氧化膦,进一步降低了成本;
4)革除了强腐蚀的毒害溶剂苯酚以及致癌溶剂氯仿和二氯乙烷,三废少,收率高,更符合绿化环保要求。
5)反应条件温和、操作简便、对设备要求低,更适合工业化生产。
附图说明
图1为本发明的基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法的催化反应路线图。
图2为本发明的基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法的催化反应机理图。
具体实施方式
为更好的理解本发明的内容,下面结合具体实施例作进一步说明。本实施例在以本发明技术方案为前提下进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
如图1所示,本发明提供了一种具体的氯喹的反应路线,经过了大量的研究,发现采用(2-羟基苄基)二取代氧化膦催化时,C-N偶联反应温度可以降低到120℃以下,而收率可以有所提高;特别是,当将使用(2-羟基-4-叔丁基苄基)二苯基氧化膦进行催化时,该C-N反应在110℃,反应20h即可顺利完成,反应条件温和可控,TLC检测显示,反应比较完全,杂质很少。推测可能的催化反应机理如图2所示。
优选实施例:
4-氨基-7-氯喹啉(20g,0.11mol)、三乙胺(12.4g,0.12mol)、200mL甲苯和40mL 二甲基亚砜,搅拌降温到0-5℃,滴加三氟甲烷磺酰氯(20.4g,0.12mol),约30min滴完,然后升到20-25℃反应4h,TLC检测原料点基本消失,停止反应。将上述反应液水洗(100 mL*2)后,搭建回流冷凝分水装置,于110C脱水1h,加入5-二乙胺基-2-戊醇(21g,0.13 mol)、(2-羟基-4-叔丁基苄基)二苯基氧化膦(P-3,3.5g,11mmol),继续回流脱水反应30h, TLC检测中间体10的点基本消失。反应结束后,将溶剂蒸干,加入100mL无水乙醇和乙醇钠(8.2g,0.12mol),在20-25℃反应8h,TLC检测中间体11的点基本消失,向反应液中加入硼氢化钾(g,40mmol),在20-25℃继续反应2h,TLC检测中间体12的点基本消失,停止反应,减压蒸掉溶剂,加入100mL二氯甲烷和100mL水,分液,水层再用100mL二氯甲烷提取1次,合并有机层,用150mL水洗1次后,将有机层与200mL水混合,搅拌下慢慢加入浓盐酸至pH=4.5,充分搅拌,氯喹成盐进入酸水层,分液,有机层旋干回收3.3g(2- 羟基-4-叔丁基苄基)二苯基氧化膦(回收率94.3%);水层加入200mL DCM,加入20%的氢氧化钠水溶液至pH=10,充分搅拌,分液,弃水层,有机层旋干得米白色氯喹粗品2.37g,经乙酸乙酯重结晶得到2.20g白色固体,收率:62.7%(以4-氨基-7-氯喹啉计),纯度99.5%。
氯喹的熔点、质谱与核磁结果:熔点:86-88℃;ESI-MS(m/z):320.18[M+H]+;1HNMR (400MHz,CDCl3)δppm:8.49(d,J=5.4Hz,1H),7.92(d,J=2.1Hz,1H),7.66(d,J=9.0Hz, 1H),7.31(dd,J=8.9,2.1Hz,1H),6.40(d,J=5.5Hz,1H),5.32(d,J=7.1Hz,1H),3.74 3.63 (m,1H),2.50(q,J=7.1Hz,4H),2.42(t,J=6.9Hz,2H),1.77 1.52(m,4H),1.29(d,J=6.3 Hz,3H),0.98(t,J=7.1Hz,6H)。
在此说明书中,本发明已参照其特定的实施例作了描述。但是,很显然仍可以作出各种修改和变换而不背离本发明的精神和范围。因此,说明书应被认为是说明性的而非限制性的。
Claims (16)
1.一种氯喹的合成方法,其特征在于,所述的合成方法包括步骤:
(1)起始原料4-氨基-7-氯喹啉与取代磺酰氯进行磺酰胺化反应制得4-取代磺酰胺基-7-氯喹啉;
(2)在(2-羟基苄基)二取代氧化膦催化下,4-取代磺酰胺基-7-氯喹啉与5-二乙胺基-2-戊醇进行C-N偶联反应;
(3)将上述反应产物在有机溶剂中经碱解反应、还原反应、回收(2-羟基苄基)二取代氧化膦、萃取、浓缩、精制得到氯喹。
2.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(1)中所述的取代磺酰氯为对硝基苯磺酰氯、对三氟甲基苯磺酰氯、甲烷磺酰氯或三氟甲基磺酰氯,优选为三氟甲基磺酰氯。
3.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(2)中所述的为(2-羟基苄基)二取代氧化膦为(2-羟基苄基)二苯基氧化膦、(2-羟基-5-叔丁基苄基)二苯基氧化膦或(2-羟基苄基)二环己基氧化膦,优选(2-羟基-5-叔丁基苄基)二苯基氧化膦。
4.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(3)中有机溶剂为四氢呋喃、甲基四氢呋喃、甲醇或乙醇等1-6个碳原子的有机醇、二氧六环、乙二醇或丙二醇的单一溶剂或混合溶剂,优选乙醇。
5.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(3)中用于碱解反应的碱为1-6个碳原子的有机醇钠、1-6个碳原子的有机醇钾、1-6个碳原子的有机醇锂、氢氧化钠、氢氧化钾、氢氧化锂、氢化钠、氨基钠、三乙胺、二异丙基乙基胺或DBU中的单一试剂或混合试剂,优选乙醇钠。
6.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(3)中用于还原反应的还原剂为硼氢化钾、硼氢化钠或氰基硼氢化钠中的单一试剂或混合试剂,优选硼氢化钾。
7.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(1)中所述的磺酰胺化反应时间为2~10h,优选4~6h;反应温度为-10~110℃,优选20~25℃。
8.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(2)中所述的C-N偶联反应时间为8~30h,优选15~20h;反应温度为60~150℃,优选100~110℃。
9.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(3)中所述的碱解反应时间为4~12h,优选6~8h;反应温度为-10~110℃,优选20~25℃。
10.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(3)中所述的还原反应时间为0.5~10h,优选1~2h;反应温度为-10~110℃,优选20~25℃。
11.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(1)中所述的4-氨基-7-氯喹啉与所述的取代磺酰氯的摩尔比为1:0.9~1:2.0,优选1:1.1~1:1.2。
12.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(2)中所述的5-二乙胺基-2-戊醇与所述的起始原料4-氨基-7-氯喹啉的摩尔比为0.9:1~2.0:1,优选1.2:1。
13.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的步骤(2)中所述的(2-羟基苄基)二取代氧化膦与所述的起始原料4-氨基-7-氯喹啉的摩尔比为0.01:1~0.2:1,优选0.05:1~0.1:1。
14.根据权利要求5所述的氯喹的合成方法,其特征在于,所述的碱与起始原料4-氨基-7-氯喹啉的摩尔比为0.9:1~2.0:1,优选1.2:1。
15.根据权利要求6所述的氯喹的合成方法,其特征在于,所述的还原剂与起始原料4-氨基-7-氯喹啉的摩尔比为0.3:1~1.0:1,优选0.35:1~0.4:1。
16.根据权利要求1所述的氯喹的合成方法,其特征在于,所述的重结晶溶剂为乙酸乙酯、乙酸异丙酯、乙酸甲酯、乙酸丁酯、丙酮、甲基异丁基酮、甲基叔丁基醚、异丙醇或甲苯的单一溶剂或混合溶剂,优选乙酸乙酯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210769396.0A CN114933562A (zh) | 2022-07-01 | 2022-07-01 | 基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210769396.0A CN114933562A (zh) | 2022-07-01 | 2022-07-01 | 基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114933562A true CN114933562A (zh) | 2022-08-23 |
Family
ID=82868724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210769396.0A Pending CN114933562A (zh) | 2022-07-01 | 2022-07-01 | 基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114933562A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693605A (zh) * | 2016-03-09 | 2016-06-22 | 西安科技大学 | 一种光学纯(r)/(s)-氯喹的不对称合成方法 |
CN111662229A (zh) * | 2020-07-08 | 2020-09-15 | 精华制药集团南通有限公司 | 一种磷酸氯喹的制备工艺 |
CN112300071A (zh) * | 2020-11-25 | 2021-02-02 | 张家港威胜生物医药有限公司 | 一种高纯度磷酸氯喹的合成方法 |
CN114308121A (zh) * | 2022-01-04 | 2022-04-12 | 浙江工业大学 | 膦氧催化剂及其制备方法和应用 |
-
2022
- 2022-07-01 CN CN202210769396.0A patent/CN114933562A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693605A (zh) * | 2016-03-09 | 2016-06-22 | 西安科技大学 | 一种光学纯(r)/(s)-氯喹的不对称合成方法 |
CN111662229A (zh) * | 2020-07-08 | 2020-09-15 | 精华制药集团南通有限公司 | 一种磷酸氯喹的制备工艺 |
CN112300071A (zh) * | 2020-11-25 | 2021-02-02 | 张家港威胜生物医药有限公司 | 一种高纯度磷酸氯喹的合成方法 |
CN114308121A (zh) * | 2022-01-04 | 2022-04-12 | 浙江工业大学 | 膦氧催化剂及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013026391A1 (zh) | 嘧菌酯及其合成中专用中间体的合成方法 | |
CN104250232A (zh) | 一种帕瑞昔布钠的制备方法 | |
CN114805314B (zh) | 一种恩赛特韦的合成方法 | |
CN110590635A (zh) | 左乙拉西坦及其中间体的制备方法 | |
CN103664923B (zh) | 硝呋太尔的制备方法 | |
CN101704796B (zh) | 3-吗啉酮制备方法 | |
CN111072499B (zh) | 一种盐酸氨溴索的合成工艺 | |
CN114933562A (zh) | 基于(2-羟基苄基)二取代氧化膦催化的氯喹的高效制备方法 | |
CN106946724B (zh) | 单胺基抑制剂类中间体2-乙酰氨基-2-苄基丙二酸单乙酯的合成方法 | |
CN109438307A (zh) | 一种l-硒代蛋氨酸的制备方法 | |
CN101367848A (zh) | 一种蔗糖-6-乙酯的制备方法 | |
CN101381297B (zh) | 一种从辛癸酸混合物中分离辛酸的方法 | |
CN114671859A (zh) | 一种瑞舒伐他汀钙及其中间体的制备方法 | |
CN108299466B (zh) | 一种改进的度鲁特韦合成方法 | |
CN111100042B (zh) | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 | |
CN107382983B (zh) | 一种治疗白血病药物的合成方法 | |
CN106748725B (zh) | 一种4-氯-2-氟-苯丙酸的制备方法 | |
US20160168161A1 (en) | Method for producing heterocyclic compound | |
CN110698381A (zh) | 一种一锅两相法合成n-(苄氧羰基)琥珀酰亚胺的方法 | |
CN111484528A (zh) | 一种替诺福韦艾拉酚胺中间体的制备方法 | |
CN105017219B (zh) | 一种p53‑MDM2结合抑制剂二羟基异喹啉衍生物的合成方法 | |
CN111039838B (zh) | 一种3-乙酰巯基-2-甲基丙酸的制备方法 | |
CN114621109B (zh) | 一种阿帕他胺的合成方法及其中间体 | |
CN112552200B (zh) | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 | |
CN115947675B (zh) | 一种雷沙吉兰中间体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |